Chinese Biopharma Firm CANbridge Life Sciences Raises $25M In Series B Round

Chinese biopharmaceutical company CANbridge Life Sciences has raised US$25 million in a series B round from lead investor Lapam Capital, a Beijing-based life science venture capital firm. Existing investor Qiming Venture Partners and new investors, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and Wuxi App Tec, also participated in the round, the company announced today.

Qiming Reaches $600M In Total Healthcare Investments

Qiming Venture Partners has invested over RMB4 billion (US$600 million) in healthcare companies in the past seven years, accounting around 40% of its aggregate invested capital, says the company in a release today. The China-focused venture firm’s healthcare team, led by managing partner Nisa Leung, made 12 healthcare investments, with an average check amount of US$10 million in 2014. "In 2016, Qiming plans to continue what it has always done: move slowly and surely forward," Nisa says. "We need to …